INT100094

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2001
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.31
Pain Relevance 0.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A4) oxidoreductase activity (CYP3A4) endoplasmic reticulum (CYP3A4)
enzyme binding (CYP3A4) lipid metabolic process (CYP3A4) cytoplasm (CYP3A4)
CYP3A4 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 3 79.84 Quite High
Serotonin 2 68.32 Quite High
rapifen 13 50.00 Quite Low
endometriosis 1 14.40 Low Low
Paracetamol 2 12.96 Low Low
Versed 8 10.00 Low Low
withdrawal 21 5.00 Very Low Very Low Very Low
headache 9 5.00 Very Low Very Low Very Low
Pain 4 5.00 Very Low Very Low Very Low
Migraine 3 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cardiovascular Disease 1 98.04 Very High Very High Very High
Endometriosis (extended) 5 88.96 High High
Head Trauma 1 62.56 Quite High
Increased Venous Pressure Under Development 1 58.28 Quite High
Miosis 2 50.00 Quite Low
Breast Cancer 1 46.24 Quite Low
Toxicity 16 37.24 Quite Low
Hemorrhage 37 19.60 Low Low
Hematuria 1 19.04 Low Low
Hepatotoxicity 1 13.56 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Compared with control, CYP3A4 induction and inhibition significantly altered the clearances of alfentanil (2.8 +/- 1.4, 5.3 +/- 1.0, and 0.42 +/- 0.1 ml/kg/min, respectively; P <.05 versus control) and midazolam.
Regulation (altered) of Positive_regulation (induction) of CYP3A4
1) Confidence 0.45 Published 2001 Journal Clin. Pharmacol. Ther. Section Body Doc Link 11753266 Disease Relevance 0 Pain Relevance 0
Predicting risks for drug–drug interactions involving CYP3A4 inactivation
Regulation (involving) of Positive_regulation (inactivation) of CYP3A4
2) Confidence 0.45 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.06 Pain Relevance 0.04
Two studies21 investigated the effects of CYP3A4 induction (study 1; E2V/DNG on days 1 to 17, rifampicin 600 mg on days 12 to 16 [n = 16]) and inhibition (study 2; E2V/DNG on days 1 to 14, ketoconazole 400 mg or erythromycin 500 mg 3 times daily on days 8 to 14 [n = 24]) on the pharmacokinetic profiles of E2 and DNG in healthy post-menopausal women.
Spec (investigated) Regulation (effects) of Positive_regulation (induction) of CYP3A4 associated with endometriosis (extended)
3) Confidence 0.03 Published 2010 Journal International Journal of Women's Health Section Body Doc Link PMC2990895 Disease Relevance 0.25 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox